Chromatin is a well-known obstacle to transcription as it controls DNA accessibility, which
directly impacts the recruitment of the transcriptional machinery. The recent burst of …

Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by
the expression of the BCR–ABL1 fusion gene with different chimeric transcripts. Despite the …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by
accumulation of immature cells in bone marrow and peripheral blood. Although successful …

The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been
proposed that it deregulates signaling networks involving both transcription factors and non …

Untreated chronic myeloid leukemia (CML) progresses from chronic phase to blastic crisis
(BC). Increased genomic instability, deregulated proliferation, and loss of differentiation …

Chronic myeloid leukemia (CML) progresses from a chronic to a blastic phase where the
leukemic cells are proliferative and undifferentiated. The CML is nowadays successfully …

Hydroxycarbamide (HC, hydroxyurea) is a cytoreductive drug inducing cell cycle blockade.
However, emerging evidence suggests that HC plays a role in the modulation of …

Epigenetic and genetic alterations are two mechanisms participating in leukemia, which can
inactivate genes involved in leukemia pathogenesis or progression. The purpose of this …

Myeloproliferative neoplasms (MPN) are multiple disease entities characterized by clonal
expansion of one or more of the myeloid lineages (ie granulocytic, erythroid, megakaryocytic …

Juvenile myelomonocytic leukemia (JMML) is characterized by myelomonocytic cell
overproduction and commonly bears activating mutations in PTPN11. Murine hematopoietic …